MYD88 and diffuse large B-cell lymphoma: Previous findings suggest a therapeutic potential for IRAK4 inhibitors for the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) presenting with MYD88 mutations, as well as for autoimmune disorders and other malignancies that depend on TLR signaling [8, 16–18].